The patients tested with a combination of its experimental drug, vibostolimab, with Keytruda experienced a higher rate of immune-related side effects, Merck said, adding that patients should stop ongoing treatment with the therapy.
News
Merck stops testing combo drug for lung cancer
August 9, 2024The patients tested with a combination of its experimental drug, vibostolimab, with Keytruda experienced a higher rate of immune-related side effects, Merck said, adding that patients should stop ongoing treatment with the therapy.